**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 78898

**Manuscript Type:** LETTER TO THE EDITOR

**Heart failure with preserved ejection fraction: A distinct heart failure phenotype?**

Triposkiadis F *et al*. HFpEF: A distinct heart failure phenotype?

Filippos Triposkiadis, Grigorios Giamouzis, John Skoularigis, Andrew Xanthopoulos

**Filippos Triposkiadis, Grigorios Giamouzis, John Skoularigis, Andrew Xanthopoulos,** Department of Cardiology, University Hospital of Larissa, Larissa 41110, Greece

**Author contributions:** Triposkiadis F and Xanthopoulos A wrote the letter; Giamouzis G and Skoularigis J revised the letter, and all authors made substantial contributions to conception and design of the study, acquisition of data, or analysis and interpretation of data; drafted the article or made critical revisions related to important intellectual content of the manuscript; and gave final approval of the version of the article to be published.

**Corresponding author: Andrew Xanthopoulos, FACC, MD, PhD, Senior Postdoctoral Fellow,** Department of Cardiology, University Hospital of Larissa, Mezourlo, Larissa 41110, Greece. andrewvxanth@gmail.com

**Received:** July 20, 2022

**Revised:** September 15, 2022

**Accepted:** October 13, 2022

**Published online:**

**Abstract**

The present work discusses the serious confusion resulting from the arbitrary nomenclature of heart failure with preserved ejection fraction (HFpEF), the presumed underlying pathophysiology, and the supposed features. A consequence of this misconception is that HFpEF trials have recruited patients with entirely different characteristics rendering the extrapolation of the results of one study to the other infeasible and dramatically affecting diagnosis and treatment.

**Key Words:** Heart failure; Preserved; Nomenclature; Left ventricular ejection fraction; Pathophysiology; Phenotypic persistence

Triposkiadis F, Giamouzis G, Skoularigis J, Xanthopoulos A. Heart failure with preserved ejection fraction: A distinct heart failure phenotype? *World J Clin Cases* 2022; In press

**Core Tip:** Heart failure (HF) with preserved left ventricular ejection fraction heart failure with preserved ejection fraction (HFpEF) raises serious confusion resulting from the arbitrary nomenclature, the presumed underlying pathophysiology, and the supposed features, all of which dramatically impact patient management. HFpEF predominantly represents a group of distinct diseases and not a specific HF phenotype which exhibits phenotypic heterogeneity.

**TO THE EDITOR**

Heart failure with preserved ejection fraction (HFpEF) [heart failure (HF) with preserved left ventricular ejection fraction (LVEF)] has been defined as HF in the presence of LVEF usually > 40%-55%. However, this HF type raises serious confusion resulting from the arbitrary nomenclature, the presumed underlying pathophysiology, and the supposed features, all of which dramatically impact patient management[1]. The nomenclature HFpEF is inappropriate as several recent studies have shown that the hazard ratios for mortality during follow-up have a U-shaped relationship for echocardiographically determined LVEF with a nadir of risk at a LVEF of 60%–65% regardless of the presence or absence of HF[2]. As a result, HF with a “supernormal” LVEF has been proposed and a HF patient with a LVEF of 45% or 50% has an abnormal and not a “preserved” LVEF. HFpEF has been attributed to a systemic proinflammatory state induced by comorbidities, including overweight/obesity, diabetes mellitus, chronic obstructive pulmonary disease, and salt-sensitive hypertension[3]. A major drawback of this conjecture, which has proved disappointing in HFpEF management, is that the relative independent contribution of the individual comorbidities to the inflammatory state, which characterizes HFpEF, has never been considered. HF is a heterogeneous syndrome in which functional and structural parameters change dynamically during disease progression in a patient-specific fashion. Therefore, HF can be regarded as a spectrum of phenotypes. Each HF phenotype is the result of a patient-specific trajectory wherein the heart remodels towards concentric hypertrophy (*i.e.* HFpEF), eccentric hypertrophy (*i.e.* HF with reduced LVEF), or a combination of both. The way of entry and the subsequent path of the trajectory depend on the patient’s risk factors, comorbidities, and disease modifiers[4,5]. Likewise, there are uncertainties regarding the widely adopted foundational features of HFpEF such as phenotypic persistence and phenotypic heterogeneity. Phenotypic persistence, which denotes the lack of significant changes in LVEF over time, is a prerequisite for establishing HFpEF as a distinct LVEF based HF phenotype[6]. However, several recent studies have demolished this conjecture. It is, therefore, not surprising that the 2022 American College of Cardiology/American Heart Association HF guidelines recommend the serial assessment and reclassification of HF trajectories based on the LVEF, ejecting the “phenotypic persistence” dogma from the frame[7]. Phenotypic heterogeneity is usually present in genetic diseases and describes the fact that even within the same family where all affected individuals share the same mutation, phenotypic variation is prominent, with variable penetrance and expressivity, presenting different degrees of involvement. A typical example is familial hypertrophic cardiomyopathy, one of the HFpEF causes, in which members of the same family may exhibit different patterns and/or severity of LV hypertrophy. In addition, phenotypic heterogeneity often occurs and in complex diseases, like coronary artery disease (CAD). In CAD a spectrum of phenotypes is observed related among others to disease onset and stability (*e.g.*, acute, or stable, recent onset or chronic, fatal, or not), extent of coronary lesions (*e.g.*, number of vessels involved, plaque composition and burden) and the severity of LV structural and functional abnormalities (*e.g.*, presence of LV dysfunction or lack thereof)[8,9]. Unfortunately, the term phenotypic heterogeneity has been erroneously used in HFpEF to denote the inclusion under the HFpEF umbrella of several distinct disease entities such as hypertension, valvular heart disease, hypertrophic cardiomyopathy, and amyloidosis. A consequence of this misconception is that HFpEF trials have recruited patients with entirely different characteristics rendering the extrapolation of the results of one study to the other infeasible and dramatically affecting diagnosis and treatment. For example, it would be irrational to extrapolate the findings of the recently published Empagliflozin Outcome Trial in Patients With Chronic Heart Failure with Preserved Ejection Fraction (EMPEROR-Preserved Trial)[10], which reported a benefit with Empagliflozin (compared with placebo) in hypertensive HFpEF (hypertension present in more than 90% of participants), to the HFpEF patients enrolled in other studies many of whom suffered from valvular heart disease or hypertrophic cardiomyopathy[6]. It has been suggested that in the realm where machine learning (ML) algorithms may aid in our understanding of phenotypically heterogeneous diseases, HFpEF may be an ideal domain in which to apply ML. ML is based on neural networks which are series of nodes or artificial neurons that are processing elements forming a series of hidden layers. Within each node there is a set of inputs, weight, and a bias value. As an input enters the node, it gets multiplied by a weight value and the resulting output is either observed or passed to the next layer in the neural network. In other words, weight is the parameter within a neural network that transforms input data within the network's hidden layers. Recent studies have reported the promising role of ML for the identification of HFpEF as well as its distinct phenotypic subgroups[11-13]. Nevertheless, further research is needed to establish these findings in larger cohorts. In summary, HFpEF predominantly represents a group of distinct diseases and not a specific HF phenotype which exhibits phenotypic heterogeneity. Moreover, even in patients with the same underlying cause (*e.g.*, hypertension) the “preserved“ LVEF may drop significantly adversely affecting prognosis and necessitating treatment changes. It is obvious that in these cases HFpEF merely represents a disease stage (*e.g.*, a stage of hypertensive HF). Whether a conglomerate of diseases or a disease stage, the continuing use of HFpEF as a distinct HF phenotype leads HF research and management to a dead end (Figure 1).

**REFERENCES**

1 **Xanthopoulos A**, Giamouzis G, Skoularigis J, Triposkiadis F. Heart failure with reduced, mildly reduced, or preserved left ventricular ejection fraction: Has reasoning been lost? *World J Cardiol* 2022; **14**: 438-445 [PMID: 36161058 DOI: 10.4330/wjc.v14.i7.438]

2 **Wehner GJ**, Jing L, Haggerty CM, Suever JD, Leader JB, Hartzel DN, Kirchner HL, Manus JNA, James N, Ayar Z, Gladding P, Good CW, Cleland JGF, Fornwalt BK. Routinely reported ejection fraction and mortality in clinical practice: Where does the nadir of risk lie? *Eur Heart J* 2020; **41**: 1249-1257 [PMID: 31386109 DOI: 10.1093/eurheartj/ehz550]

3 **Paulus WJ**, Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. *J Am Coll Cardiol* 2013; **62**: 263-271 [PMID: 23684677 DOI: 10.1016/j.jacc.2013.02.092]

4 **Triposkiadis F**, Butler J, Abboud FM, Armstrong PW, Adamopoulos S, Atherton JJ, Backs J, Bauersachs J, Burkhoff D, Bonow RO, Chopra VK, de Boer RA, de Windt L, Hamdani N, Hasenfuss G, Heymans S, Hulot JS, Konstam M, Lee RT, Linke WA, Lunde IG, Lyon AR, Maack C, Mann DL, Mebazaa A, Mentz RJ, Nihoyannopoulos P, Papp Z, Parissis J, Pedrazzini T, Rosano G, Rouleau J, Seferovic PM, Shah AM, Starling RC, Tocchetti CG, Trochu JN, Thum T, Zannad F, Brutsaert DL, Segers VF, De Keulenaer GW. The continuous heart failure spectrum: Moving beyond an ejection fraction classification. *Eur Heart J* 2019; **40**: 2155-2163 [PMID: 30957868 DOI: 10.1093/eurheartj/ehz158]

5 **De Keulenaer GW**, Brutsaert DL. The heart failure spectrum: time for a phenotype-oriented approach. *Circulation* 2009; **119**: 3044-3046 [PMID: 19506105 DOI: 10.1161/CIRCULATIONAHA.109.870006]

6 **Lupón J**, Gavidia-Bovadilla G, Ferrer E, de Antonio M, Perera-Lluna A, López-Ayerbe J, Domingo M, Núñez J, Zamora E, Moliner P, Santiago-Vacas E, Santesmases J, Bayés-Genis A. Heart Failure With Preserved Ejection Fraction Infrequently Evolves Toward a Reduced Phenotype in Long-Term Survivors. *Circ Heart Fail* 2019; **12**: e005652 [PMID: 30827137 DOI: 10.1161/CIRCHEARTFAILURE.118.005652]

7 **Heidenreich PA**, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *J Am Coll Cardiol* 2022; **79**: e263-e421 [PMID: 35379503 DOI: 10.1016/j.jacc.2021.12.012]

8 **Rezende PC**, Scudeler TL, da Costa LM, Hueb W. Conservative strategy for treatment of stable coronary artery disease. *World J Clin Cases* 2015; **3**: 163-170 [PMID: 25685763 DOI: 10.12998/wjcc.v3.i2.163]

9 **Zhang JF**, Du YH, Hu HY, Han XQ. Ultrasonographic assessment of cardiac function and disease severity in coronary heart disease. *World J Clin Cases* 2021; **9**: 8366-8373 [PMID: 34754846 DOI: 10.12998/wjcc.v9.i28.8366]

10 **Anker SD**, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, Brunner-La Rocca HP, Choi DJ, Chopra V, Chuquiure-Valenzuela E, Giannetti N, Gomez-Mesa JE, Janssens S, Januzzi JL, Gonzalez-Juanatey JR, Merkely B, Nicholls SJ, Perrone SV, Piña IL, Ponikowski P, Senni M, Sim D, Spinar J, Squire I, Taddei S, Tsutsui H, Verma S, Vinereanu D, Zhang J, Carson P, Lam CSP, Marx N, Zeller C, Sattar N, Jamal W, Schnaidt S, Schnee JM, Brueckmann M, Pocock SJ, Zannad F, Packer M; EMPEROR-Preserved Trial Investigators. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. *N Engl J Med* 2021; **385**: 1451-1461 [PMID: 34449189 DOI: 10.1056/NEJMoa2107038]

11 **Unterhuber M,** Rommel K-P, Kresoja K-P, Lurz J, Kornej J, Hindricks G, Scholz M, Thiele H, Lurz P. Deep learning detects heart failure with preserved ejection fraction using a baseline electrocardiogram. *Eur Heart J - Digital Health* 2021; **2**: 699-703 [DOI: 10.1093/ehjdh/ztab081]

12 **Segar MW**, Patel KV, Ayers C, Basit M, Tang WHW, Willett D, Berry J, Grodin JL, Pandey A. Phenomapping of patients with heart failure with preserved ejection fraction using machine learning-based unsupervised cluster analysis. *Eur J Heart Fail* 2020; **22**: 148-158 [PMID: 31637815 DOI: 10.1002/ejhf.1621]

13 **Woolley RJ**, Ceelen D, Ouwerkerk W, Tromp J, Figarska SM, Anker SD, Dickstein K, Filippatos G, Zannad F, Metra M, Ng L, Samani N, van Veldhuisen DJ, Lang C, Lam CS, Voors AA. Machine learning based on biomarker profiles identifies distinct subgroups of heart failure with preserved ejection fraction. *Eur J Heart Fail* 2021; **23**: 983-991 [PMID: 33651430 DOI: 10.1002/ejhf.2144]

**Footnotes**

**Conflict-of-interest statement:** All the authors report no relevant conflicts of interest for this article.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** July 20, 2022

**First decision:** September 5, 2022

**Article in press:**

**Specialty type:** Medicine, research and experimental

**Country/Territory of origin:** Greece

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C, C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Feng R, China; Leslie SJ, United Kingdom **S-Editor:** Liu XF **L-Editor:** A **P-Editor:** Liu XF

**Figure Legends**



**Figure 1 It is irrational to believe that the management of a group of diseases covered under the term heart failure with preserved ejection fraction should be based on a single biomarker, namely the left ventricular ejection fraction, as the Empagliflozin Outcome Trial in Patients with Chronic Heart Failure with Preserved Ejection Fraction implies.** It is noteworthy, that like all trials which demonstrated a potential benefit with medical treatment in heart failure with preserved ejection fraction, more than 90% of the patients in Empagliflozin Outcome Trial in Patients with Chronic Heart Failure with Preserved Ejection Fraction were hypertensive and, in contrast to other HFpEF trials, patients with valvular heart disease or hypertrophic cardiomyopathy were not included suggesting a selection bias. LV: Left ventricular; CPX: Cardiopulmonary exercise testing; 6MW: 6 min walk test; LVER: Left ventricular ejection fraction; HFpEF: Heart failure with preserved ejection fraction.